Peripheral blood monocyte M2/M1 ratio for the diagnosis of breast cancer

doi:10.3969/j.issn.1673-8640.2018.05.011

Abstract

Abstract:

Objective To compare the difference of peripheral blood monocyte M2/M1 ratio between breast cancer patients and healthy subjects,and to investigate the role of peripheral blood monocyte M2/M1 ratio as a circulating tumor marker. Methods Flow cytometry was used to determine peripheral blood monocyte M2/M1 ratio in 89 patients with breast cancer and 53 healthy subjects. The results of carcinoembryonic antigen （CEA） and carbohydrate antigen15-3 （CA15-3） determinations were analyzed comparatively. Results The peripheral blood monocyte M2/M1 ratio in patients with breast cancer was higher than that in healthy subjects（P<0.001）. The area under receiver operating characteristic （ROC）curve of peripheral blood monocyte M2/M1 ratio determination was bigger than those of CEA and CA15-3 determinations. Conclusions The application of flow cytometry in determining peripheral blood monocyte M2/M1 ratio for breast cancer patients is of high diagnostic significance. Peripheral blood monocyte M2/M1 ratio may become a new circulating tumor marker for the diagnosis of breast cancer.

Key words: Monocyte M2/M1 ratio, Tumor-associated macrophage, Circulating tumor marker, Breast cancer

CLC Number:

R446.62

DU Yan, LIU Hua, ZHANG Boke, LIU Yiwen, HE Yiqing, YANG Cuixia, ZHANG Guoliang, GAO Feng. Peripheral blood monocyte M2/M1 ratio for the diagnosis of breast cancer[J]. Laboratory Medicine, 2018, 33(5): 421-424.

Figures/Tables 4

References 13

[1]	DESANTIS C, MA J, BRYAN L, et al.Breast cancer statistics, 2013[J]. CA Cancer J Clin, 2014, 64(1): 52-62.
[2]	DUFFY M J, WALSH S, MCDERMOTT E W, et al.Biomarkers in breast cancer: where are we and where are we going?[J]. Adv Clin Chem, 2015, 71: 1-23.
[3]	SICA A, LARGHI P, MANCINO A, et al.Macrophage polarization in tumour progression[J]. Semin Cancer Biol, 2008, 18(5): 349-355.
[4]	ZHANG G, GUO L, YANG C, et al.A novel role of breast cancer-derived hyaluronan on inducement of M2-like tumor-associated macrophages formation[J]. Oncoimmunology, 2016, 5(6): e1172154.
[5]	ROUSSOS E T, BALSAMO M, ALFORD S K, et al.Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer[J]. J Cell Sci, 2011, 124(Pt 13): 2120-2131.
[6]	ADAMS D L, MARTIN S S, ALPAUGH R K, et al.Circulating giant macrophages as a potential biomarker of solid tumors[J]. Proc Natl Acad Sci U S A, 2014, 111(9): 3514-3519.
[7]	LI C, LUO X, LIN Y, et al.A higher frequency of CD14+ CD169+ monocytes/macrophages in patients with colorectal cancer[J]. PLoS One, 2015, 10(10): e0141817.
[8]	JONES K, VARI F, KEANE C, et al.Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma[J]. Clin Cancer Res, 2013, 19(3): 731-742.
[9]	陆宁,佟仲生. 肿瘤相关巨噬细胞在乳腺癌中的研究进展[J]. 国际免疫学杂志,2014,37(2):122-125.
[10]	MAEDA R, ISHII G, NERI S, et al.Circulating CD14+CD204+ cells predict postoperative recurrence in non-small-cell lung cancer patients[J]. J Thorac Oncol, 2014, 9(2): 179-188.
[11]	ZHANG B, CAO M, HE Y, et al.Combination of plasma HA and circulating M2-like monocytes may serve as a diagnostic marker for breast cancer[J]. J Cancer, 2017, 8(17): 3522-3530.
[12]	MIRABELLI P, INCORONATO M.Usefulness of traditional serum biomarkers for management of breast cancer patients[J]. Biomed Res Int, 2013, 2013: 685641.
[13]	陈彼得,吴三纲,何振宇,等. 术前CEA和CA15-3对乳腺癌的临床应用价值[J]. 现代肿瘤医学,2012,20(8):1610-1613.

组别	例数	CA15-3 （U/mL）	CEA （ng/mL）	M2/M1单核细胞比例	白细胞计数（×10⁹/L）	单核细胞计数（×10⁹/L）
乳腺癌组	89	10.56（7.68~15.27）^*	1.68（1.05~2.18）	0.166±0.110^**	5.58±1.53	0.31±0.12
体检健康组	53	9.06（2.63~12.40）	1.40（1.00~1.89）	0.090±0.032	5.39±1.11	0.33±0.10

组别	例数	CA15-3 （U/mL）	CEA （ng/mL）	M2/M1单核细胞比例	白细胞计数（×10⁹/L）	单核细胞计数（×10⁹/L）
乳腺癌组	89	10.56（7.68~15.27）^*	1.68（1.05~2.18）	0.166±0.110^**	5.58±1.53	0.31±0.12
体检健康组	53	9.06（2.63~12.40）	1.40（1.00~1.89）	0.090±0.032	5.39±1.11	0.33±0.10

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[3]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[4]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[5]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[6]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[7]	WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820.
[8]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[9]	YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348.
[10]	ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40.
[11]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[12]	YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329.
[13]	LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158.
[14]	JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486.
[15]	MEI Zhaoling, ZHOU Wenhui, FENG Jing. The Progress of Exosomes Application in Diagnosis and Treatmeat of breast cancer [J]. Laboratory Medicine, 2020, 35(12): 1203-1206.